Finally, in vitro and in vivo studies have demonstrated that combination therapies, with PPAR-γ agonists together with other anticancer drugs, including drugs targeting the IGF system, may provide benefit for the treatment of certain human cancers. This evidence concerns the gene PPARG and cancer.